Gynecologic Oncology

Hanneke Poort, PhD, discusses research regarding fatigue as an adverse event in patients with gynecologic cancer.

The FDA has granted a priority review designation to a supplemental new drug application for the combination of olaparib and bevacizumab for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to first-line platinum-based chemotherapy with bevacizumab.

Matthew P. Schlumbrecht, MD, discusses the role of surgical resection in uterine leiomyosarcoma.

Floor J. Backes, MD, discusses the phase III FILM trial in endometrial cancer.

Matthew P. Schlumbrecht, MD, discusses ongoing challenges in diagnosing uterine leiomyosarcoma.

Mira Hellmann, MD, gynecologic oncologist and assistant professor, John Theurer Cancer Center, Hackensack University Medical Center, discusses the use of sentinel lymph node mapping in patients with endometrial cancer.

Mira Hellmann, MD, gynecologic oncologist and assistant professor, John Theurer Cancer Center, Hackensack University Medical Center, discusses the evolution of surgical techniques in endometrial cancer.

Casey M. Cosgrove, MD, gynecologic oncologist, The Ohio State University Comprehensive Cancer Center–James, and assistant professor, Department of Gynecologic Oncology, The Ohio State University College of Medicine, discusses retreatment with PARP inhibitors in recurrent ovarian cancer.

Sarah Ferguson, MD, FRCSC, discusses the rationale to conduct a population-based cohort study comparing the efficacy of minimally invasive surgery versus open surgery for radical hysterectomy in women with cervical cancer.

China’s National Medical Products Administration has granted marketing authorization for olaparib as a first-line maintenance treatment for adult patients with newly diagnosed advanced germline or somatic BRCA-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to frontline platinum-based chemotherapy.

The UK’s National Institute for Health and Care Excellence has approved olaparib for the maintenance treatment of adult patients with relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease responded to platinum-based chemotherapy and harbor BRCA1/2 mutations.

Sarah Crafton, MD, discusses the role of secondary surgical cytoreduction in recurrent ovarian cancer.

When discussing the topic of vaccination to prevent serious childhood illness, an increasing number of individuals refuse to accept the unequivocally demonstrated value of this public health strategy despite the very low risk of harm.

Floor J. Backes, MD, discusses subtle differences among PARP inhibitors that can help determine their optimal use in advanced ovarian cancer.

John Hays, MD, PhD, discusses ongoing research with immunotherapy in ovarian cancer, challenges with determining predictive biomarkers of response, and promising emerging modalities.

Larry J. Copeland, MD, discusses how therapy for patients with ovarian cancer has evolved in recent years.

Ritu Salani, MD, discusses the potential of targeted therapy and immunotherapy in cervical cancer.

Experts from The Ohio State University and Allegheny Health Network discuss the exciting research being conducted at their institutions.

Ritu Salani, MD, discusses the evolution of up-front chemotherapy, as well as the roles of primary debulking surgery and neoadjuvant chemotherapy in ovarian cancer.

David O’Malley, MD, discusses clinical trials in ovarian cancer and others under investigation.

Leigha Senter, MS, LGC, discusses the current state of genetic testing for patients with ovarian cancer.

Charles A. Leath III, MD, gynecologic oncologist at the University of Alabama at Birmingham, discusses agents under investigation in cervical cancer.

Robert L. Coleman, MD, FACOG, FACS, discusses ongoing research efforts in cervical cancer.

Floor J. Backes, MD, discusses the safety profile from a phase I study looking at lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

Ghanshyam Yadav, MD, discusses the differences between type 1 and type 2 uterine cancer.